BLOCK in Medical Technology
Navigation Links
BLOCK in Medical Technology
...
The Change of Upper Limbs PVI in Spinal block (Comparison in High Spinal block and Non-High Spinal Block)
At the Tokai ... changed in response to the level of spinal block reached. PVI was recorded in all patients before ...
... and thrombin is the most potent activator of platelets. Drugs that block platelet activation by other mechanisms, such as the thromboxane- or ... (when added to standard of care), a tendency associated with drugs that block thromboxane or ADP pathways. Specifically, this compound is being ...
... work by other researchers had shown that monoclonal antibodies that block the IL12 or IL23 receptor show some clinical success in treating Crohn's ... but with side effects to the immune system," said Baldassano. "If we can block other molecules further downstream on a pathway, we may achieve better ...
... programs to develop small molecule or monoclonal antibody approaches to block the binding of HIV to CCR5. However, a small molecule or antibody ... of a sufficiently high concentration of these drugs or antibody to block therapeutically relevant numbers of the CCR5 protein, which is present in ...
... and clinical evidence that supports the further development of drugs that block the glutamate cascade," said Dr. Kurtz. "As the American Headache Society ... By acting at both the AMPA and kainate receptor site to competitively block the binding of glutamate, tezampanel and its oral prodrug, NGX426, have ...
... and thrombin is the most potent activator of platelets. Drugs that block platelet activation by other mechanisms, such as the thromboxane- or ... (when added to standard of care), a tendency associated with drugs that block thromboxane or ADP pathways. Specifically, this compound is being ...
... NMBA currently available." About the Signal trial(1) This profound block trial was a multicenter, parallel-group study among adult patients ... curarization. About the Spectrum trial(2) In this second profound block trial, 110 patients undergoing elective surgery requiring short duration ...
... in Chicago. The findings demonstrated that small molecule agents which block the activity of ExsA (a MAR protein) in Pseudomonas aeruginosa ... resistance. Paratek is advancing novel compounds that can circumvent or block bacterial resistance involving technology initially developed by Paratek ...
... Inc. announced that in an article published today in Nature Medicine, Proteolix's selective immunoproteasome inhibitor PR-957 was shown to block disease progression in mouse models of rheumatoid arthritis in a dose-dependent manner and to completely eliminate visible signs of disease at the ...
... the most widely used drugs in the world for the treatment of arthritis and pain and are a major cause of GI complications, including ulcers. NSAIDs block enzymes and reduce prostaglandins throughout the body and as a consequence, ongoing inflammation, pain, and fever are reduced. Because the ...
... SSRIs included Celexa(R) (citalopram), Lexapro(R) (escitalopram) and Luvox(R) (fluvoxamine). "We've known that these CYP2D6 inhibitor drugs block the activation of tamoxifen chemically, but this is the first time there's evidence that these drugs are putting women at a much higher risk for ...
... of drug candidates addressing these targets. Semafore is also leveraging its experience in the PI3K arena to identify and design inhibitors that block multiple pathways. For more information visit the Company's web site at www.SemaforePharma.com . ...
... of many cancer cells, including certain leukemias, lymphomas and other cancers. Preclinical laboratory experiments have shown that MDX-1338 can block the growth of, and even directly kill, selected human tumor cells. The Phase 1, open-label, multicenter, dose-escalation study of MDX-1338 as ...
... of drug candidates addressing these targets. Semafore is also leveraging its experience in the PI3K arena to identify and design inhibitors that block multiple pathways. For more information see the company's web site at www.SemaforePharma.com . ...
... 40 mg of olmesartan medoxomil will prevent or delay the occurrence of microalbuminuria in comparison to a regimen that excludes agents that directly block the RAS. The secondary objective is to test the hypothesis that treatment with olmesartan medoxomil has a positive effect on cardiovascular and renal ...
... Tissue Safety. "This unique collaborative effort between federal government and the private sector has great potential to be a critical building block for a national biovigilance program, which has as a common goal to improve patient safety and donor health." For more information about the ....
... of research in pain management as well as cancer treatment. We look forward to working with our colleagues at Harvard to explore the potential to block pain without affecting motor or other functions, and with the team at Aurigene to discover new oncology drug candidates." About Endo Endo ...
... of a muscle cell in the heart or blood vessels or rate of electrical firing or production of chemical messengers in nerve cells. Calcium antagonists block calcium channels. There are many types of calcium channels. Medicines can be selective to bind just with one type (e.g. heart and blood vessels to ...
... Results of this study will also help identify the recommended dose for Phase 2 trials. The IAP inhibitors are a novel class of compounds that block the activity of IAP (inhibitor of apoptosis) proteins, thus allowing apoptosis to proceed and causing the cancer cells to die. When IAP proteins are ...
Semafore Achieves a Preclinical Milestone with SF2626, a PI3K-MEK Dual Pathway Kinase Inhibitor
... that EGFR inhibitors alone are not sufficient to block the downstream activation of the Ras-MAPK pathway. In these patients, it may also be necessary to block both pathways to inhibit cancer cell growth. ... PI3K arena to identify and design inhibitors that block multiple pathways. For more information ...Parasites That Live Inside Cells Use Loophole to Thwart Immune System
... from St. Jude scientists shows how microbes can block nitric oxide production - a chemical key to the ... that it might be feasible to develop drugs to block such pathogens' biochemical subversion, restoring ... in macrophages grown in the culture dishes can block nitric oxide production in macrophages by ...Pharmacopeia Announces Third Quarter 2007 Financial Results
... -- PS433540 demonstrated its ability to block the increase in blood pressure induced by ... similar studies with other agents that block the renin-angiotensin system support that this ... successfully demonstrated its ability to block the angiotensin II- induced blood pressure ...TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
... binds to certain AK receptors to potentially block the transmission of pain signals, has been ... bind to certain AK receptors to block transmission of pain signals mediated through the ... of glutamate receptors. Because they do not block opioid receptors or constrict blood vessels, the ...Cognition Therapeutics Closes Series A Financing to Advance Drug Candidates for Alzheimer's Disease
... advancement of Cognition Therapeutics' pioneering lead molecules that block the activity of the toxic oligomeric form of Abeta protein that interferes ... diseases, and there are currently no therapeutics available to prevent or block the destructive effects of toxic oligomeric proteins. Cognition has ...Novel Vaccine Approach Offers Hope in Fight Against HIV
... developers. By using gene transfer technology that produces molecules that block infection, the scientists protected monkeys from infection by a virus ... (called immunoadhesins) that were specifically designed to bind to SIV and block it from infecting cells. Once proven to work against SIV in the ...... and thrombin is the most potent activator of platelets. Drugs that block platelet activation by other mechanisms, such as the thromboxane- or ... (when added to standard of care), a tendency associated with drugs that block thromboxane or ADP pathways. Specifically, this compound is being ...
... work by other researchers had shown that monoclonal antibodies that block the IL12 or IL23 receptor show some clinical success in treating Crohn's ... but with side effects to the immune system," said Baldassano. "If we can block other molecules further downstream on a pathway, we may achieve better ...
Hope for Progeria - Successfully Validated on Mice, a Treatment Could Soon be Tested on Children
... protein (whilst it is eliminated in normal cells). In order to inhibit or block the toxicity of progerin, the researchers explored the path of synthesis of this fatty acid. In fact, pharmacological molecules are known to block certain stages in this path of synthesis. After several attempts they ...... programs to develop small molecule or monoclonal antibody approaches to block the binding of HIV to CCR5. However, a small molecule or antibody ... of a sufficiently high concentration of these drugs or antibody to block therapeutically relevant numbers of the CCR5 protein, which is present in ...
... and clinical evidence that supports the further development of drugs that block the glutamate cascade," said Dr. Kurtz. "As the American Headache Society ... By acting at both the AMPA and kainate receptor site to competitively block the binding of glutamate, tezampanel and its oral prodrug, NGX426, have ...
Indevus Pharmaceuticals Reports Positive Results of Phase II Octreotide Implant Trial
... is a synthetic peptide that mimics the natural hormone somatostatin to block release of GH. In the recently completed six-month trial, the octreotide ... a long-acting octapeptide that mimics the natural hormone somatostatin to block release of growth hormone (GH), over a six month period. About Indevus ...... and thrombin is the most potent activator of platelets. Drugs that block platelet activation by other mechanisms, such as the thromboxane- or ... (when added to standard of care), a tendency associated with drugs that block thromboxane or ADP pathways. Specifically, this compound is being ...
... NMBA currently available." About the Signal trial(1) This profound block trial was a multicenter, parallel-group study among adult patients ... curarization. About the Spectrum trial(2) In this second profound block trial, 110 patients undergoing elective surgery requiring short duration ...
... in Chicago. The findings demonstrated that small molecule agents which block the activity of ExsA (a MAR protein) in Pseudomonas aeruginosa ... resistance. Paratek is advancing novel compounds that can circumvent or block bacterial resistance involving technology initially developed by Paratek ...
Schering-Plough Initiates Phase III Studies with Vicriviroc in Treatment- Experienced HIV Patients
... Next-Generation Once-Daily CCR5 Antagonist Designed to block HIV Infection of Immune System Cells KENILWORTH, ... is a next-generation extracellular inhibitor of HIV infection designed to block entry of infectious virions into uninfected CD4 cells via antagonism of ...Popular Breast Cancer Drug Used with Certain Antidepressants Puts New Jersey Women at Risk
... those that could put them in the at-risk population. "We've been aware that certain antidepressants, known as CYP2D6 inhibitor drugs, block the activation of tamoxifen chemically, but this evidence shows that these drugs are putting women in New Jersey and across the nation at a much ...June 2009 Mayo Clinic Women's HealthSource Highlights Summer Skin Problems, Low Vision and Pilates
... in soft, lightweight, loose-fitting cotton clothing can help prevent heat rash. Avoiding powders and heavy creams can help, too; these products can block skin pores. Treatment -- Sweat reduction and keeping the skin cool help clear up the rash. (Think air conditioning.) Cool-water compresses, ...... Inc. announced that in an article published today in Nature Medicine, Proteolix's selective immunoproteasome inhibitor PR-957 was shown to block disease progression in mouse models of rheumatoid arthritis in a dose-dependent manner and to completely eliminate visible signs of disease at the ...
Boehringer Ingelheim Unveils Diabetes Pipeline
... sodium-dependent glucose co-transporter-2 inhibitors (SGLT-2 inhibitors), which are a new, emerging class of antidiabetic compounds that block tubular reabsorption of glucose in the kidney.(4) Phase IIb clinical trials for this innovative approach to diabetes treatment are underway. There ...... the most widely used drugs in the world for the treatment of arthritis and pain and are a major cause of GI complications, including ulcers. NSAIDs block enzymes and reduce prostaglandins throughout the body and as a consequence, ongoing inflammation, pain, and fever are reduced. Because the ...
... SSRIs included Celexa(R) (citalopram), Lexapro(R) (escitalopram) and Luvox(R) (fluvoxamine). "We've known that these CYP2D6 inhibitor drugs block the activation of tamoxifen chemically, but this is the first time there's evidence that these drugs are putting women at a much higher risk for ...
New Research Shows Antidepressants May Thwart Breast Cancer Treatment
... the past few years, to give physicians and patients reason to question using certain antidepressants (and other types of medications that might block the CYP2D6 enzyme) together with tamoxifen." Tamoxifen has been used to successfully treat millions of women diagnosed with ...... of drug candidates addressing these targets. Semafore is also leveraging its experience in the PI3K arena to identify and design inhibitors that block multiple pathways. For more information visit the Company's web site at www.SemaforePharma.com . ...
... of many cancer cells, including certain leukemias, lymphomas and other cancers. Preclinical laboratory experiments have shown that MDX-1338 can block the growth of, and even directly kill, selected human tumor cells. The Phase 1, open-label, multicenter, dose-escalation study of MDX-1338 as ...
... of drug candidates addressing these targets. Semafore is also leveraging its experience in the PI3K arena to identify and design inhibitors that block multiple pathways. For more information see the company's web site at www.SemaforePharma.com . ...
... 40 mg of olmesartan medoxomil will prevent or delay the occurrence of microalbuminuria in comparison to a regimen that excludes agents that directly block the RAS. The secondary objective is to test the hypothesis that treatment with olmesartan medoxomil has a positive effect on cardiovascular and renal ...
... Tissue Safety. "This unique collaborative effort between federal government and the private sector has great potential to be a critical building block for a national biovigilance program, which has as a common goal to improve patient safety and donor health." For more information about the ....
New Analysis Evaluated Impact of Genetic Variation on Response to Prasugrel
... narrowed or clogged by cholesterol and fat deposits and cannot supply enough blood to the heart. In some cases, a blood clot may partially or totally block the blood supply to the heart resulting in ACS.(6) Many ACS patients are managed with PCI, which usually includes a stent placement. About ...Study Confirms: Your Hidden Food Allergies Are Making You Fat
... exposure to incompatible foods, is at the root of metabolic problems like diabetes, cardiovascular disease and obesity. The immune system chemicals block insulin receptors; so, guess what happens to the sugars we eat? - they get stored as fat. Cut the inflammation, cut the fat storage." Along with ...Radius Initiates Phase 2a Clinical Trial of RAD1901 in Menopausal Hot Flashes
... therapy. SERMs are small molecules that bind to and selectively modulate estrogen receptors. These molecules have the ability to stimulate or block estrogen's activity in different types of tissue, functioning as estrogen receptor agonists in some tissues and as estrogen receptor antagonists in ...Freezing Prostate Cancer Does a Man's Body Good
... below the bladder and in front of the rectum). Prostate cancer affects one in six men, usually older men. As men age, the prostate may get bigger and block the urethra or bladder. This may cause difficulty in urination or can interfere with sexual function. It is estimated that there are more than 2 ...... of research in pain management as well as cancer treatment. We look forward to working with our colleagues at Harvard to explore the potential to block pain without affecting motor or other functions, and with the team at Aurigene to discover new oncology drug candidates." About Endo Endo ...
Pieris Reports Development Progress for Anticalin(R) PRS-050, a Next Generation VEGF Antagonist
... have already been granted in the US, Asia and Europe. About PRS-050 PRS-050 Anticalin(R) has been designed to specifically bind and block the signaling activity of vascular endothelial growth factor (VEGF) in cancer. Optimised for extended serum half-life, PRS-050 exhibits comparable ...Mayo Clinic Study Finds Younger Men With Erectile Dysfunction at Double Risk of Heart Disease
... erectile dysfunction and coronary artery disease may be different manifestations of the same underlying disease process. A buildup of plaque that can block arteries around the heart may plug the smaller penile arteries first, causing erectile dysfunction. Alternatively, arteries may lose elasticity over ...Nanoemulsion Kills Highly Resistant Bacteria Found in Patients With Cystic Fibrosis
... activity in the presence of cystic fibrosis sputum and against bacterial biofilms, protective coatings that surround bacterial colonies and block the penetration of drugs. "Based on preclinical and clinical safety data from NanoBio's topical anti-infective products, we believe that we ...... of a muscle cell in the heart or blood vessels or rate of electrical firing or production of chemical messengers in nerve cells. Calcium antagonists block calcium channels. There are many types of calcium channels. Medicines can be selective to bind just with one type (e.g. heart and blood vessels to ...
Chemoembolization Improving as Liver Cancer Treatment
... it), and then release the drug once in the body, as well as modifications to uniformity and size of the beads themselves so that they can more fully block the blood vessel and further guard against potential leakage of blood that could feed the tumor. More than 21,000 people are diagnosed with ...... Results of this study will also help identify the recommended dose for Phase 2 trials. The IAP inhibitors are a novel class of compounds that block the activity of IAP (inhibitor of apoptosis) proteins, thus allowing apoptosis to proceed and causing the cancer cells to die. When IAP proteins are ...
Other ContentsgravitygravitygravitygravitygravityurologyurologyurologyurologyurologyurticariaprolapseprolapseprolapseurogenitalurogenitalusherusherfibroidsfibroidsuterineuterineuterineuterineuterineuterineOther TagsthingsMaxMaxMaxMaxMaxmimicsemergeemergeemergepossibilitiesretrievalretrievalhurtmovemovemovemoveOther Tagsdozen 2dozen 3dozen 4dozen 5dozen 6dozen 7dozen 8positively 2positively 3positively 4positively 5positively 6fully 2fully 3fully 4fully 5fully 6fully 7fully 8fully 9fully 10sensory 2sensory 3sensory 4sensory 5sensory 6sensory 7crop 2crop 3crop 4crop 5crop 6crop 7pulses 2pulses 3field 2field 3field 4field 5field 6field 7field 8field 9field 10
(Date:12/3/2009)In the 1980s, Harald zur Hausen and his co-workers discovered that specific types of human papillomavirus (HPV) cause cervical cancer. Scientists soon found out how these pathogens cause cells to dege
(Date:12/3/2009)PHILADELPHIA Now in its 32nd year, the CTRC-AACR San Antonio Breast Cancer Symposium continues to attract the best in breast cancer science and world leaders from industry and academia with the goal
(Date:12/3/2009)Forest dwellers must be included in the design of the upcoming forest deal at Copenhagen in order to avoid a humanitarian crisis, according to a scientist at the University of Leeds. , Writing today
Breaking Biology News(10 mins):Papillomavirus silences innate immune response 2CTRC-AACR San Antonio Breast Cancer Symposium continues to expand 2Forest deal at Copenhagen must avoid creating 'carbon refugees' 2HBA Global Announces Finalists for the 2009 International Package Design Awards 28IPDA 29 55290 1HBA Global Announces Finalists for the 2009 International Package Design Awards 28IPDA 29 55290 2HBA Global Announces Finalists for the 2009 International Package Design Awards 28IPDA 29 55290 3CardioDx Completes Validation Study of First Of Its Kind Genomic Test for Coronary Artery Disease 4894 1CardioDx Completes Validation Study of First Of Its Kind Genomic Test for Coronary Artery Disease 4894 2CardioDx Completes Validation Study of First Of Its Kind Genomic Test for Coronary Artery Disease 4894 3CardioDx Completes Validation Study of First Of Its Kind Genomic Test for Coronary Artery Disease 4894 4Adamas Pharmaceuticals Expands Management Team 3B Names Michael D Coffee and Amy K Patick to Executive Positions 55287 1Adamas Pharmaceuticals Expands Management Team 3B Names Michael D Coffee and Amy K Patick to Executive Positions 55287 2Adamas Pharmaceuticals Expands Management Team 3B Names Michael D Coffee and Amy K Patick to Executive Positions 55287 3Adamas Pharmaceuticals Expands Management Team 3B Names Michael D Coffee and Amy K Patick to Executive Positions 55287 4(Date:12/5/2009)Research debunks the ,something,s wrong with being single, myth , , SATURDAY, Dec. 5 (HealthDay News) -- Pity the poor single people who pass their 40th birthday without ever tying the knot, s
(Date:12/4/2009)PALO ALTO, Calif., Dec. 4 Varian Medical Systems (NYSE: VAR ) announced today that its Board of Directors has set the regular 2010 Annual Meeting of Stockholders for February 11, 2010 with a record
(Date:12/4/2009)WASHINGTON, Dec. 4 The American Association of Homes and Services for the Aging (AAHSA) applauds the Senate for ensuring that the Community Living and Supportive Services (CLASS) provisions remain i
(Date:12/4/2009)WASHINGTON, Dec. 4 While Congress debates whether health care reform would control health care costs, Leapfrog,s purchaser members point to 45 hospitals that lead through example -- delivering the be
(Date:12/4/2009)Case Western Reserve University researchers, from the School of Medicine,s Department of Nutrition, discovered two new metabolic pathways by which products of lipid peroxidation and some drugs of abus
Breaking Medicine News(10 mins):Health News:Never Married, Over 40, Well-Adjusted 2Health News:Never Married, Over 40, Well-Adjusted 3Health News:Varian Medical Systems Schedules Annual Stockholder Meeting in Palo Alto 2Health News:The Leapfrog Group Releases Its 2009 Top Hospitals List 2Health News:The Leapfrog Group Releases Its 2009 Top Hospitals List 3Health News:Case Western Reserve researchers' new pathway discovery published as 'Paper of the Week' 2[0] Never Married, Over 40, Well-Adjusted[0] Varian Medical Systems Schedules Annual Stockholder Meeting in Palo Alto[0] Statement from AAHSA CEO Larry Minnix on the Failure of the Thune Amendment[0] The Leapfrog Group Releases Its 2009 Top Hospitals List[0] Case Western Reserve researchers' new pathway discovery published as 'Paper of the Week'
| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |